Susquehanna International Group
KNTE

Susquehanna International Group’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Susquehanna International Group’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-526,021
Closed -$1.4M – 13590
2024
Q1 		$1.4M Buy
526,021
+219,952
+72% +$545K ﹤0.01% 6163
2023
Q4 		$725K Buy
306,069
+160,591
+110% +$284K ﹤0.01% 7774
2023
Q3 		$204K Buy
145,478
+387
+0.3% +$929 ﹤0.01% 10190
2023
Q2 		$440K Buy
145,091
+104,906
+261% +$404K ﹤0.01% 8603
2023
Q1 		$251K Buy
+40,185
New +$245K ﹤0.01% 10111
2022
Q3 		– Sell
-12,130
Closed -$159K – 14381
2022
Q2 		$153K Buy
+12,130
New +$113K ﹤0.01% 11002
2022
Q1 		– Sell
-11,640
Closed -$128K – 14241
2021
Q4 		$206K Buy
+11,640
New +$245K ﹤0.01% 11385

Susquehanna International Group's KNTE Position: Q2 2024 in Review

Susquehanna International Group sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 526,021 shares — an estimated $1.4M sold.

Susquehanna International Group first reported a position in KNTE in Q4 2021 and held it in 7 quarters. The position peaked at $1.4M in Q1 2024. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Susquehanna International Group reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Susquehanna International Group sold 526,021 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $1.4M.
  • Susquehanna International Group first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2021 and held it in 7 quarters.
  • Susquehanna International Group's Kinnate Biopharma Inc. Common Stock position peaked at $1.4M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Susquehanna International Group's 13F filing for Q2 2024, filed 15 Aug 2024.